从SCAD到CCS,疾病名称的变更,是我们对治疗领域深入了解,寻求更好治疗方案的过程......
总结 [2]Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407‐477. doi:10.1093/eurheartj/ehz425. [3]胡盛寿,高润霖,刘力生, 等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34 (3):209-220. [4]国家卫生计生委合理用药专家委员会,中国药师协会. 冠心病合理用药指南(第2 版).中国医学前沿杂志(电子版).2018;10(6):1-126. [5]HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279‐1291. [6]Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther. 2019;12:5467‐5484. [7]Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266‐272. [8]Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy [published correction appears in Drug Saf. 2007;30(8):726]. Drug Saf. 2005;28(3):263‐275. [9]王鹏,严妍,于文君,李妍.他汀类药物不良反应的研究进展.中国医院药学杂志, 2016,36(22):2035-2039. [10]血脂异常老年人使用他汀类药物中国专家共识[J].中华内科杂志,2015,49(5):535-542. [11]李萍,王春燕.他汀类药物与常见心血管药物的相互作用分析[J].中国药业,2019, 28(07):88-90. 看过,请点这里 |
|